Fed. Circ. Backs USPTO's Term Adjustment For Drug Patent

Law360 (February 6, 2018, 9:09 PM EST) -- The Federal Circuit said Tuesday that Actelion Pharmaceuticals Ltd. was not entitled to a patent term adjustment that would have added several days to the life of a patent beyond an adjustment the U.S. Patent and Trademark Office granted, upholding a lower court’s decision.

The appeals court said the USPTO did not err in its decision to extend the term of Actelion’s patent, related to a treatment for lupus, by 40 days to compensate for delays in the patent examination process. Actelion had asked for 45...
To view the full article, register now.

Documents

Related

Sections

Case Information

Case Title

Actelion Pharmaceuticals, Ltd. v. Iancu


Case Number

17-1238

Court

Appellate - Federal Circuit

Nature of Suit

830 Patent Infringement (Fed. Question)

Date Filed

November 18, 2016

Law Firms

Companies

Government Agencies

Patents

Judge Analytics

Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.